article thumbnail

Rheumatology Board Meeting Summary | Spring 2025

ABIM

Dave, MD, MPH , inquired how stressors may contribute to candidates failing the certification examination and Dr. McDonald stated that knowledge gaps were the primary cause, though ABIM provides safeguards to reduce stress like grace periods and consideration of compassionate exemptions for extraordinary life circumstances.

article thumbnail

Nurse Practitioners Critical in Treating Older Adults as Ranks of Geriatricians Shrink

Physician's Weekly

Johnson and her husband, Dustin, operate an NP-led private practice in greater Seattle, Washington, a state where she can practice independently. “We step into places where other providers may not, and geriatrics is a prime example of that.” nurse practitioners can practice independently.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nephrology Board Meeting Summary | Spring 2025

ABIM

Practice types, size and ownership models vary widely, but more than half of respondents indicated that they work in private practice, with a single-specialty group practice as the predominant structure and independent or physician-owned practice the predominant ownership model.

article thumbnail

Endocrinology, Diabetes and Metabolism Board Meeting Summary | Spring 2025

ABIM

Reddy, MPH, Senior Research Associate in Assessment and Research at ABIM reviewed aggregate data gathered so far related to endocrinologists, including practice setting, practice size and physician ownership of practices. Community Practice in ABIM Governance* Erica N.

article thumbnail

Hematology Board Meeting Summary | Spring 2025

ABIM

Preliminary data show that 90% of respondents are clinically active with the majority in hospital- or system-owned practice (38%), academic faculty practice (32.9%) and private practice (26.8%). Most (49.5%) are in single-specialty group practice or multi-specialty group practice (38%).

article thumbnail

FDA’s Accelerated Approval of Biogen’s Aduhelm for Alzheimer’s: A Sign of Applying the Emergency Use Standard Beyond COVID?

FDA Law Blog

It is noteworthy that this sentence that no clinical benefit has been established was deemed by FDA as unnecessary for Aduhelm to provide additional context beyond that the approval is based on reduction in amyloid beta plaques. be “reasonably likely to predict” ultimate clinical benefit).

Clinic 98